New personalized cancer vaccine in initial human clinical trial in advanced ovarian cancer patients found half of vaccinated patients showed signs of anti-tumor responses and lived longer. One patient, after 2 years of vaccinations, was disease-free for another 5 years without further treatment.

New personalized cancer vaccine in initial human clinical trial in advanced ovarian cancer patients found half of vaccinated patients showed signs of anti-tumor responses and lived longer. One patient, after 2 years of vaccinations, was disease-free for another 5 years without further treatment.: https://ift.tt/2qxhUh0 Read more... https://ift.tt/2qyTKm7